SEQ-1274

SEQ-1274 is a novel, chemically synthesized small molecule microtubule inhibitor developed by Sequoia Vaccines. It binds to the colchicine-binding site on tubulin, disrupting microtubule formation and function. This mechanism targets the structural integrity of cancer cells, leading to cell cycle arrest and apoptosis. SEQ-1274 has demonstrated potent activity against over 50 human cancer cell lines—including ovarian, lung, breast, colon, CNS, melanoma, prostate, renal, and uterine cancers—and shows efficacy in several taxane-resistant lines. In preclinical studies and animal tumor models conducted at multiple independent laboratories (including research led by Washington University), SEQ-1274 was more active than paclitaxel in ovarian and uterine cancer models and reduced expression of AXL protein associated with drug resistance[1][6]. The compound is currently in preclinical development for high-grade ovarian cancer and potentially other solid tumors[1][2][3].